Orthofix Medical's (OFIX) Market Perform Rating Reaffirmed at JMP Securities

Orthofix Medical (NASDAQ:OFIX - Get Free Report)'s stock had its "market perform" rating restated by JMP Securities in a note issued to investors on Friday,Benzinga reports.

A number of other research firms have also weighed in on OFIX. Roth Mkm reaffirmed a "buy" rating and set a $22.00 price target on shares of Orthofix Medical in a report on Wednesday, February 26th. Wall Street Zen downgraded Orthofix Medical from a "buy" rating to a "hold" rating in a report on Wednesday, May 7th. Finally, Canaccord Genuity Group reissued a "buy" rating and issued a $24.00 price target on shares of Orthofix Medical in a report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $23.33.

Orthofix Medical Trading Up 2.4%

OFIX traded up $0.26 during trading on Friday, hitting $10.97. 633,357 shares of the company's stock were exchanged, compared to its average volume of 274,344. Orthofix Medical has a 1 year low of $10.50 and a 1 year high of $20.73. The stock has a 50 day moving average price of $12.82 and a 200 day moving average price of $16.07. The firm has a market cap of $429.82 million, a P/E ratio of -3.50 and a beta of 0.80. The company has a current ratio of 2.39, a quick ratio of 1.11 and a debt-to-equity ratio of 0.25.

Insider Buying and Selling at Orthofix Medical

In other Orthofix Medical news, insider Jorge Andres Cedron sold 3,816 shares of the company's stock in a transaction that occurred on Wednesday, April 16th. The stock was sold at an average price of $13.31, for a total transaction of $50,790.96. Following the sale, the insider now owns 42,500 shares in the company, valued at $565,675. This represents a 8.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Lucas Vitale sold 4,287 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $16.60, for a total value of $71,164.20. Following the sale, the insider now owns 135,317 shares in the company, valued at $2,246,262.20. The trade was a 3.07% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have bought 112,250 shares of company stock worth $1,380,970 and have sold 8,475 shares worth $128,065. 1.30% of the stock is currently owned by insiders.

Institutional Trading of Orthofix Medical

Several large investors have recently added to or reduced their stakes in the business. Engine Capital Management LP increased its position in Orthofix Medical by 8.4% in the 1st quarter. Engine Capital Management LP now owns 3,741,390 shares of the medical device company's stock valued at $61,022,000 after acquiring an additional 290,646 shares during the period. Vanguard Group Inc. boosted its stake in Orthofix Medical by 2.6% during the 1st quarter. Vanguard Group Inc. now owns 2,181,313 shares of the medical device company's stock valued at $35,577,000 after purchasing an additional 54,528 shares in the last quarter. Juniper Investment Company LLC boosted its stake in Orthofix Medical by 10.3% during the 1st quarter. Juniper Investment Company LLC now owns 2,137,374 shares of the medical device company's stock valued at $34,861,000 after purchasing an additional 200,125 shares in the last quarter. Boone Capital Management LLC boosted its stake in Orthofix Medical by 13.6% during the 4th quarter. Boone Capital Management LLC now owns 1,057,313 shares of the medical device company's stock valued at $18,461,000 after purchasing an additional 126,806 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Orthofix Medical by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 841,637 shares of the medical device company's stock valued at $14,699,000 after purchasing an additional 2,448 shares in the last quarter. 89.76% of the stock is currently owned by institutional investors and hedge funds.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.